RESULTS
Among the 26,866,600 persons who died during the 13-year study period, 1,932 decedents had death records with ICD-9 code 277.6 listed. We excluded 2 death records in which codes consistent with hereditary angioedema were present for a total of 1,930 death records that we included in this analysis. ocs-Antitrypsin deficiency (ICD-9 277.6) was the UCD in 1,432 (74.1%) of the 1930 deaths, whereas obstructive pulmonary disease was the UCD in 172 deaths (8.9%); atherosclerotic cardiovascular disease was the UCD in 55 (2.9%) deaths, and hepatic disease was the UCD in 51 (2.6%) deaths.
Obstructive pulmonary disease was the complication most frequently listed with ox1-antitrypsin defi- occurring among infants younger than 1 year old and for 1.2% ofthese deaths among children 1-14 years old ( Table 2 ). Fourteen of the 1,930 decedents had a code for hepatic cancer listed on their death certificate.
The median age of death increased from 46 years of age in 1979 to 52 years ofage in 1991. The age-adjusted mortality rate with a-l-antitrypsin deficiency listed increased 86.0%, from 4.3 per 10,000,000 in 1979 to 8.0 per 10 million in 1991. The age-adjusted mortality rate with a1-antitrypsin disease present increased among both men and women during the 13-year study period (Fig 1) . Mortality rates were consistently higher among men than women both in every year of the study and in every age stratum except for the 65-74 years age group. a,-Antitrypsin deficiency mortality rates were also consistently higher among whites than among blacks or people of other races (Fig 2) .
Age-specific mortality rates of otl-antitrypsin deficiency vere highest among infants younger than 1 year old and lowest among people aged 1-34 years (Fig 3) . Rates among persons 35-64 years old and 65 years and older were similar and increased over the study period (Fig 3) . When we compared the number of deaths of persons with ai-antitrypsin deficiency to the total number ofdeaths, we detected 2 peaks, the first among the 1-14 year olds (41.90 per 100,000 deaths) and another among 45-54 year olds (35.49 per 100,000 deaths).
The age-adjusted death rates with a,-antitrypsin varied among states from the lowest rate, 2.5 per 10 million in New Jersey, to the highest, 22.5 per 10 million in Maine.
DIsCUSSION
The main role of ot,-antitrypsin, which is produced primarily in the liver,9 is to defend the lower respiratory tract against neutrophil elastase.10 The ao1 allele, which is coded for by the polymorphic a, gene, determines the serum level of otl-antitrypsin.11 More than 75 versions of these alleles exist, and they are categorized on the basis of the status of ao-antitrypsin in the serum. Mutations in the coding exons of the a1 gene result in low serum and lung levels of a1-antitrypsin.12 Combinations of deficient alleles (S or Z family) and null alleles result in decreased protection against neutrophil elastase, thereby predisposing affected individuals to developing lung disease. The phenotype, which is determined on the basis of serum al-antitrypsin level, designates the magnitude of risk and the kind of disease for which the individual is at risk.'3 Serum al-antitrypsin levels (referenced to functional antielastase activity) range from deficient (<11 pmol/L), to low (11 to 20 plmol/L), to normal (>20 pmol/L).14 People who inherit the PiZ or PiMmaiton alleles are at an increased risk of developing liver disease.9 Although the progression of liver disease occurs differently among children than among adults, the pathogenesis for both involves the intracellular accumulation of al-antitrypsin within the rough endoplasmic reticulum of the hepatocytes.'5 We found cxl-antitrypsinassociated hepatic disease listed most frequently among younger decedents (Tables 1 and 2 ). Hepatic disease, which occurs in about 10% of all Pi ZZ newborns, initially occurs as hepatitis with cholestasis, but sometimes progresses to cirrhosis and liver failure in late childhood and early adolescence. 15 We determined that the age-adjusted mortality rate was consistently higher among men than among women in every age group except the 65-74 year olds. Because this deficiency is not a sex-linked genetic disorder, the most likely explanation for this finding is a diagnostic bias by clinicians. The higher occurrence of obstructive lung disease related to aol-antitrypsin deficiency among male subjects could be attributed to cigarette smoking, as smoking has been more common among male subjects.19 Results of a study of a1-antitrypsin-deficient patients showed that the patients who had smoked were dying an average of 10 years earlier than the nonsmokers.3 Another explanation for higher rates ofoxl-antitrypsin deficiency mortality among men is that men are more likely to be employed in dusty occupations, such as mining and construction, which are linked to obstructive lung disease. 20 We also found a higher rate of oxl-antitrypsin disease mortality among men than women among persons younger than age 35 years, when liver disease is the major cause of mortality. The reasons for this finding are unclear but would not be related to smoking or other exposure factors.
We also observed geographic variability of reported cx1-antitrypsin mortality rates in the United States, with age-adjusted mortality rates ranging from 2.5 per 10 million in New Jersey to 22.5 per 10 million in Maine. The reasons for this finding are unclear but may be related to differences in regional gene pools, differing racial composition of different states, or an ascertainment and reporting bias by physicians. cx,-antitrypsin deficiency was noted to be present among 2 to 3% of some younger groups of decedents with obstructive lung disease, but in much lower proportions among older age groups with obstructive lung disease. Our study has several limitations. The code we searched for, ICD-9 277.6, is used to indicate both a,-antitrypsin deficiency and hereditary angioedema, which may be present in as many as 1 in 10,000 people. Hereditary angioedema is not linked to either obstructive lung disease or hepatic disease, as oxl-antitrypsin deficiency is. We searched for laryngeal edema, which is linked to mortality from hereditary angioedema, and eliminated subjects with this diagnosis from the study. It is possible, however, that some ofthe subjects we included may have had the diagnosis of hereditary angioedema. Another limitation of the database is that we are dependent on both physicians recognizing that disease is present and listing this disease on death certificates. Many persons with ox1-antitrypsin deficiency are nonsmokers who have normal lung function.18 It is doubtful that such persons would be recognized as having a deficiency and having it noted on their death certificates. Conversely, most persons with obstructive lung disease do not have (x1-antitrypsin deficiency.31,7 Thus, the upward trend we detected is most likely related to improved recognition of the deficiency among both younger and older persons with obstructive lung disease rather than to an increasing prevalence. Because death certificates are dependent on a physician's judgment in recording the causes of death, it is also possible that some persons without a deficiency, such as MZ heterozygotes, may have been included in the database.
New therapies for cx,-antitrypsin deficiency include augmentation therapy,"1 pharmacologic ffierapy,22
gene therapy,23 and transplantation.'3 The best treatment, especially for prevention of severe obstructive lung disease, might be early recognition and encouragement not to smoke. '8 CONCLUSION We determined that the mortality rate of reported cul-antitrypsin deficiency increased over the study period, and the mortality rates reported for this disease were higher among men than women and among whites than people of other races. We detected 2 mortality peaks, 1 among children and 1 among persons aged 45-54 years old, a finding that reflects that this deficiency manifests itself in two ways: as hepatic failure among children and as obstructive lung disease among adults. The increase in mortality rates we detected is probably due to improved diagnosis and increased recognition, although this deficiency is still likely underreported, especially among older persons with obstructive lung disease.
